Humanigen HGEN Stock News

Humanigen Inc (OTCMKTS: HGEN) is likely to head for the top in the market after the opening bell this morning. The company announced that the FDA has given the green light for it to move forward with a Phase III clinical trial of a potential COVID-19 treatment. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

HGEN Stock To Climb On Phase III COVID-19 Trial

In the press release, Humanigen said that the FDA has given it permission to move forward with a Phase III clinical trial. Through the trial, the company will assess lenzilumab as a potential treatment option for COVID-19 patients.

The copany said that patients will be enrolled in the trial that are COVID-19 positive and hospitalized as a result of pneumonia associated with the condition. Should all go well, lenzilumab will reduce the risk of respiratory failure and/or death in this patient population.

In a statement, Dr. Cameron Durrant, CEO at HGEN, had the following to offer:

We are working with some of the top centers and clinicians in the US, alongside our contract research organization partner, CTI, to bring lenzilumab rapidly through this clinical study which, if successful, may reduce serious and potentially fatal outcomes in patients hospitalized with COVID-19 and at high risk of progression.

Lenzilumab has demonstrated an excellent safety and tolerability profile in other disease settings, including severe asthma. As the only company that has been working on prevention of cytokine storm through GM-CSF neutralization for nearly three years, we have published extensively in this field and filed extensive IP. We plan to bring this experience to the COVID-19 setting and recruit patients into this Phase III study as quickly as possible.

This Is Incredible News

HGEN is in a very good spot at the moment. Ultimately, their treatment is designed to reduce the risk of cytokine storm, a COVID-19 related complication that leads to ARDS and death in many patients. In previous trials, the treatment has shown efficacy in the prevention of cytokine storm in cancer patients treated with CAR-T therapies. So, similar results are expected in this trial, and that’s big news.

Think about it, COVID-19 has changed the very shape of humanity as we know it. We used to reach out for communication and social activities. Now, we shun them. Our children used to go to school. Now, they study at home. We used to be able to go to the barber to get our hair cut, but that non-essential type of business has been shut down.

The bottom line is that as COVID-19 changes the very fabric of society, vaccines and treatments are in very high demand. These are our only tools that can eventually bring us back to a sense of normalcy, and Humanigen has one.

While there are a few companies working on treatments, HGEN is one of only a small handful that are ready and moving toward the clinic. As such, this is a stock that’s well worth watching.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Get Free Alerts

Join our free mailing list to receive stock alerts!

This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and Humanigen, CNA Finance has been hired for a period beginning on 3/23/20 and ending on 4/23/20 to conduct digital advertising and marketing and publicly disseminate information about HGEN via Websites and Email. We have an agreement and are currently owed $10,000 by via bank wire transfer to cover the cost of content production. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and Humanigen has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.